Remedies for infant chronic arthritis-relating diseases

• US 20040115197A1
• Filed: 09/29/2003
• Published: 06/17/2004
• Est. Priority Date: 04/02/2001
• Status: Abandoned Application

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Minota, Seiji, Nishimoto, Norihiro, Iwamoto, Masahiro, Yoshizaki, Kazuyuki, Yokota, Shumpei, Miyamae, Takako
• Application Number:
  US10/473,165
• Publication Number:
  US 20040115197A1
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still'"'"'s disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

1. A therapeutic agent for chronic arthritides diseases of childhood-related diseases comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

2. A therapeutic agent for chronic arthritides diseases of childhood comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

3. The therapeutic agent for chronic arthritides diseases of childhood according to claim 2 wherein the IL-6 antagonist is an antibody against IL-6 receptor.

4. The therapeutic agent for chronic arthritides diseases of childhood according to claim 3 wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

5. The therapeutic agent for chronic arthritides diseases of childhood according to claim 4 wherein the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

6. The therapeutic agent for chronic arthritides diseases of childhood according to claim 4 wherein the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

7. The therapeutic agent for chronic arthritides diseases of childhood according to any one of claims 3 to 6 wherein the antibody against IL-6 receptor is a recombinant antibody.

8. The therapeutic agent for chronic arthritides diseases of childhood according to claim 5 wherein the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

9. The therapeutic agent for chronic arthritides diseases of childhood according to claim 6 wherein the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

10. The therapeutic agent for chronic arthritides diseases of childhood according to any one of claims 3 to 5 wherein the antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.

11. The therapeutic agent for chronic arthritides diseases of childhood according to claim 10 wherein the humanized antibody against IL-6 receptor is humanized PM-1 antibody.

12. The therapeutic agent for chronic arthritides diseases of childhood according to any one of claims 2 to 11 wherein said chronic arthritides diseases of childhood are:

in the ARA classification, systemic onset, olyarticular, and pauciarticular;

in the EULAR classification, systemic onset, polyarticular, and oligoarticular;

in the ILAR classification, systemic onset, polyarticular (RF positive), polyarticular (RF negative), oligoarthritis, and extended oligoarthritis;

in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RF)-positive type, b. anti-nuclear antibody (ANA)-positive type, c. RF/ANA-negative type)).

13. The therapeutic agent for chronic arthritides diseases of childhood according to any one of claims 2 to 11 wherein said chronic arthritides diseases of childhood are:

in the ARA classification, systemic onset and polyarticular;

in the EULAR classification, systemic onset and polyarticular;

in the ILAR classification, systemic onset, polyarticular (RF positive), polyarticular (RF negative), and extended oligoarthritis;

in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RA)-positive type, b. anti-nuclear antibody (ANA)-positive type)).

14. The therapeutic agent for chronic arthritides diseases of childhood according to any one of claims 2 to 11 wherein said chronic arthritides diseases of childhood are:

in the ARA classification, systemic onset and polyarticular;

in the EULAR classification, systemic onset and polyarticular;

in the ILAR classification, systemic onset, polyarticular (RF positive), and extended oligoarthritis;

in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RF)-positive type)).

15. A therapeutiac agent for Still'"'"'s disease comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

16. The therapeutic agent for Still'"'"'s disease according to claim 15 wherein an interleukin-6 antagonist is an antibody against IL-6 receptor.

17. The therapeutic agent for Still'"'"'s disease according to claim 16 wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

18. The therapeutic agent for Still'"'"'s disease according to claim 17 wherein the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

19. The therapeutic agent for Still'"'"'s disease according to claim 17 wherein the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

20. The therapeutic agent for Still'"'"'s disease according to any one of claims 16 to 19 wherein the antibody against IL-6 receptor is a recombinant antibody.

21. The therapeutic agent for Still'"'"'s disease according to claim 18 wherein the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

22. The therapeutic agent for Still'"'"'s disease according to claim 19 wherein the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

23. The therapeutic agent for Still'"'"'s disease according to any one of claims 16 to 18 wherein the antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.

24. The therapeutic agent for Still'"'"'s disease according to claim 23 wherein the humanized antibody against IL-6 receptor is humanized PM-1 antibody.

25. The therapeutic agent for Still'"'"'s disease according to any one of claims 15 to 24 wherein Still'"'"'s disease is adult Still'"'"'s disease.

26. The therapeutic agent for Still'"'"'s disease according to any one of claims 15 to 24 wherein Still'"'"'s disease is Still'"'"'s disease of children.